Johnson & Johnson's MedTech Momentum Expected To Rebound In 2025 Despite Current Hurdles: Analyst

Financial Performance - Johnson & Johnson reported a fourth-quarter adjusted EPS of $2.04, down 10.9% year over year, but beating the consensus estimate of $2.01 [1] - The company achieved sales of $22.52 billion, reflecting a 5.3% year-over-year increase and surpassing the consensus of $22.44 billion [1] - Operational growth was recorded at 6.7%, with adjusted operational growth at 5.7% [1] Segment Performance - The MedTech segment remains weak, facing challenges from increased competition and foreign exchange issues, although initial 2025 EPS guidance was slightly better than expected [2][4] - The oncology segment performed strongly, particularly the multiple myeloma franchise, while the immunology segment faced challenges with Tremfya [7] Analyst Insights - Analysts from Raymond James noted that increased M&A activity could support long-term growth, but near-term challenges include soft electrophysiology performance and the impact of Stelara's loss of exclusivity [3] - BofA Securities views Johnson & Johnson as fairly valued, with a slight reduction in price forecast from $160 to $159, maintaining a Neutral rating [4] - Stifel analysts expect MedTech growth to pick up in the second half of 2025, despite current pressures, and maintained a Hold rating [6] Stock Performance - Johnson & Johnson's stock was up 1% at $146.80 at the last publication [7]